X-ray Micro-tomography Validation of HRCT-Based Airway Measurements. This project brings together a newly emergent modality of microscopy in the form of 3D X-ray micro-tomography (XRMT) along with leading-edge image analysis to develop breakthrough science in respiratory research aimed at improving the reliability of high resolution computed tomography (HRCT). The project will develop novel 3D lung image segmentation protocols, a stereotactic registration program allowing 3D matching of XRCT and ....X-ray Micro-tomography Validation of HRCT-Based Airway Measurements. This project brings together a newly emergent modality of microscopy in the form of 3D X-ray micro-tomography (XRMT) along with leading-edge image analysis to develop breakthrough science in respiratory research aimed at improving the reliability of high resolution computed tomography (HRCT). The project will develop novel 3D lung image segmentation protocols, a stereotactic registration program allowing 3D matching of XRCT and HRCT data sets, and a validation protocol for quantitative HRCT analysis of airway disease. These outcomes will allow wider application of HRCT to non-invasively follow the dynamics of pulmonary function.Read moreRead less
Development of the PD GeneChip: a research and diagnostic tool for Parkinson's disease. The PD GeneChip will provide both social and economic benefits to Australia. It will be a key research platform for Australian scientists, and will facilitate collaboration both within Australia and overseas. It will assist with health care management of PD (Parkinson's disease) patients by providing a cost-effective diagnostic tool and the possibility of predicting the clinical course of disease. This inform ....Development of the PD GeneChip: a research and diagnostic tool for Parkinson's disease. The PD GeneChip will provide both social and economic benefits to Australia. It will be a key research platform for Australian scientists, and will facilitate collaboration both within Australia and overseas. It will assist with health care management of PD (Parkinson's disease) patients by providing a cost-effective diagnostic tool and the possibility of predicting the clinical course of disease. This information will provide the basis for tailoring treatment to a patients needs. It is anticipated that marketing of the PD GeneChip within Australia and overseas may produce revenue of at least $40 million annually.Read moreRead less